| Market Cap | 33.12M | P/E | - | EPS this Y | 21.40% | Ern Qtrly Grth | - |
| Income | -4.68M | Forward P/E | -6.14 | EPS next Y | 27.30% | 50D Avg Chg | 4.00% |
| Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | 141.00% |
| Dividend | N/A | Price/Book | 5.46 | EPS next 5Y | - | 52W High Chg | -80.00% |
| Recommedations | 2.50 | Quick Ratio | 6.04 | Shares Outstanding | 27.76M | 52W Low Chg | 713.00% |
| Insider Own | 6.74% | ROA | -67.76% | Shares Float | 25.19M | Beta | 1.60 |
| Inst Own | 3.60% | ROE | -119.56% | Shares Shorted/Prior | 469.93K/327.19K | Price | 1.78 |
| Gross Margin | - | Profit Margin | - | Avg. Volume | 803,680 | Target Price | 1.40 |
| Oper. Margin | - | Earnings Date | Nov 11 | Volume | 441,574 | Change | -5.82% |
Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It also develops IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Innovative Med Concepts, LLC and changed its name to Virios Therapeutics, Inc. in July 2020. The company was founded in 2012 and is headquartered in Alpharetta, Georgia.
| Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Duncan Gregory Scott | CHIEF EXECUTIVE OFFI.. CHIEF EXECUTIVE OFFICER | Aug 17 | Buy | 1.2498 | 25,000 | 31,245 | 57,461 | 08/18/23 |
| Whitley Richard James | Director Director | Dec 08 | Sell | 0.2591 | 1,800 | 466 | 700 | 12/12/22 |
| Walsh Angela | SVP OF FINANCE SVP OF FINANCE | May 23 | Buy | 4.575 | 2,000 | 9,150 | 3,000 | 05/24/22 |
| Duncan Gregory Scott | CHIEF EXECUTIVE OFFI.. CHIEF EXECUTIVE OFFICER | May 23 | Buy | 4.52 | 7,500 | 33,900 | 32,461 | 05/24/22 |
| Pridgen William | Director Director | May 17 | Buy | 4.3802 | 13,450 | 58,914 | 36,469 | 05/18/22 |
| Pridgen William | Director Director | Mar 29 | Buy | 4.9408 | 600 | 2,964 | 23,019 | 03/30/22 |
| Pridgen William | Director Director | Mar 23 | Buy | 5.4627 | 2,197 | 12,002 | 22,419 | 03/24/22 |
| De La Rosa Abel | Director Director | Jan 07 | Buy | 5.896 | 4,000 | 23,584 | 4,000 | 01/07/22 |